GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mesoblast Ltd (NAS:MESO) » Definitions » Cash Flow from Financing

Mesoblast (Mesoblast) Cash Flow from Financing : $67.82 Mil (TTM As of Dec. 2023)


View and export this data going back to 2010. Start your Free Trial

What is Mesoblast Cash Flow from Financing?

Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.

For the three months ended in Dec. 2023, Mesoblast received $39.71 Mil more from issuing new shares than it paid to buy back shares. It spent $1.10 Mil paying down its debt. It paid $0.00 Mil more to buy back preferred shares than it received from issuing preferred shares. It received $0.00 Mil from paying cash dividends to shareholders. It spent $3.79 Mil on other financial activities. In all, Mesoblast earned $34.82 Mil on financial activities for the three months ended in Dec. 2023.


Mesoblast Cash Flow from Financing Historical Data

The historical data trend for Mesoblast's Cash Flow from Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mesoblast Cash Flow from Financing Chart

Mesoblast Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Cash Flow from Financing
Get a 7-Day Free Trial Premium Member Only Premium Member Only 71.61 131.10 108.53 -9.87 74.50

Mesoblast Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cash Flow from Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.01 -2.54 38.76 -3.22 34.82

Mesoblast Cash Flow from Financing Calculation

This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.

Mesoblast's Cash from Financing for the fiscal year that ended in Jun. 2023 is calculated as:

Mesoblast's Cash from Financing for the quarter that ended in Dec. 2023 is:


Cash Flow from Financing for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $67.82 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Mesoblast  (NAS:MESO) Cash Flow from Financing Explanation

Cash from financing contains six items:

1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.

Mesoblast's issuance of stock for the three months ended in Dec. 2023 was $39.71 Mil.

2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.

Mesoblast's repurchase of stock for the three months ended in Dec. 2023 was $0.00 Mil.

3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.

Mesoblast's net issuance of debt for the three months ended in Dec. 2023 was $-1.10 Mil. Mesoblast spent $1.10 Mil paying down its debt.

4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

Mesoblast's net issuance of preferred for the three months ended in Dec. 2023 was $0.00 Mil. Mesoblast paid $0.00 Mil more to buy back preferred shares than it received from issuing preferred shares.

5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

Mesoblast's cash flow for dividends for the three months ended in Dec. 2023 was $0.00 Mil. Mesoblast received $0.00 Mil from paying cash dividends to shareholders.

6. Other Financing:
Money spent or earned by company from other financial activities.

Mesoblast's other financing for the three months ended in Dec. 2023 was $-3.79 Mil. Mesoblast spent $3.79 Mil on other financial activities.


Mesoblast Cash Flow from Financing Related Terms

Thank you for viewing the detailed overview of Mesoblast's Cash Flow from Financing provided by GuruFocus.com. Please click on the following links to see related term pages.


Mesoblast (Mesoblast) Business Description

Traded in Other Exchanges
Address
Level 38, 55 Collins Street, Melbourne, VIC, AUS, 3000
Mesoblast Ltd is a clinical-stage biotechnology company. It develops and commercializes innovative allogeneic cellular medicines to treat complex diseases resistant to the conventional standard of care. Its portfolio of Phase 3 product candidates comprises remestemcel-L for the treatment of steroid-refractory acute graft versus host disease (SR-aGVHD), and for moderate to severe acute respiratory distress syndrome (ARDS) and others.